- Jun 14, 2022
- 1 min read

ESMO CONGRESS September 2022

Updated: Aug 22, 2022

We look forward to presenting at ESMO in September.

Recent Posts

RS Oncology to present translational data identifying potential biomarkers associated with RSO-021 anticancer activity.

Recent advancements in treating malignant pleural mesothelioma, and why localized treatment could be advantageous

RS Oncology Announces First Patient Dosed in Phase 2 Clinical Study (MITOPE) Investigating RSO-021 for the Treatment of Malignant Pleural Mesothelioma and Metastatic Disease to the Lung

Cambridge, MA, USA and Leicester, UK, February 1, 2024 -- RS Oncology (RSO), a clinical stage biotechnology company developing innovative therapies to eradicate mesothelioma and other diseases, today

ESMO CONGRESS September 2022

Recent Posts

Subscribe to our newsletter • Don’t miss out!